Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00577824
First received: December 18, 2007
Last updated: June 6, 2014
Last verified: June 2014
Results First Received: November 23, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Interventions: Drug: exenatide
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
5mcg Exenatide BID exenatide SC 5mcg, twice daily
10mcg Exenatide BID exenatide SC 10mcg, twice daily
Placebo BID placebo SC, twice daily

Participant Flow:   Overall Study
    5mcg Exenatide BID     10mcg Exenatide BID     Placebo BID  
STARTED     72 [1]   73     36  
Full Analysis Set     72 [2]   72     35  
COMPLETED     65     53     34  
NOT COMPLETED     7     20     2  
Adverse Event                 6                 18                 1  
Patient decision                 0                 1                 1  
Protocol Violation                 1                 1                 0  
[1] Started=Randomized
[2] Full Analysis Set=subject received at least one dose of study medication (active or placebo)



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
5mcg Exenatide BID exenatide SC 5mcg, twice daily
10mcg Exenatide BID exenatide SC 10mcg, twice daily
Placebo BID placebo SC, twice daily
Total Total of all reporting groups

Baseline Measures
    5mcg Exenatide BID     10mcg Exenatide BID     Placebo BID     Total  
Number of Participants  
[units: participants]
  72     72     35     179  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     53     46     27     126  
>=65 years     19     26     8     53  
Age  
[units: years]
Mean ± Standard Deviation
  58.5  ± 9.33     59.4  ± 9.75     56.3  ± 11.41     58.4  ± 9.94  
Gender  
[units: participants]
       
Female     23     23     11     57  
Male     49     49     24     122  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24   [ Time Frame: baseline, 24 weeks ]

2.  Secondary:   Percentage of Patients Achieving HbA1c < 7.0%   [ Time Frame: 24 weeks ]

3.  Secondary:   Percentage of Patients Achieving HbA1c < 6.5%   [ Time Frame: 24 weeks ]

4.  Secondary:   Change in Fasting Blood Glucose   [ Time Frame: baseline, week 24 ]

5.  Secondary:   Change in Body Weight   [ Time Frame: baseline, week 24 ]

6.  Secondary:   Change in Total Cholesterol   [ Time Frame: baseline, week 24 ]

7.  Secondary:   Change in Low Density Lipoprotein Cholesterol (LDL-C)   [ Time Frame: baseline, week 24 ]

8.  Secondary:   Change in High Density Lipoprotein Cholesterol (HDL-C)   [ Time Frame: baseline, week 24 ]

9.  Secondary:   Change in Triglycerides   [ Time Frame: baseline, week 24 ]

10.  Secondary:   Change in Waist Size   [ Time Frame: baseline, week 24 ]

11.  Secondary:   Change in Waist-to-hip Ratio   [ Time Frame: baseline, week 24 ]

12.  Secondary:   7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24   [ Time Frame: baseline, week 24 ]

13.  Secondary:   Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)   [ Time Frame: baseline, week 24 ]

14.  Secondary:   Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)   [ Time Frame: baseline, week 24 ]

15.  Secondary:   Change in Serum Insulin   [ Time Frame: baseline, week 24 ]

16.  Secondary:   Change in C-peptide   [ Time Frame: baseline, week 24 ]

17.  Secondary:   Change in 1,5-anhydroglucitol   [ Time Frame: baseline, week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
e-mail: clinicaltrials@amylin.com


No publications provided by AstraZeneca

Publications automatically indexed to this study:

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00577824     History of Changes
Other Study ID Numbers: H8O-JE-GWBB
Study First Received: December 18, 2007
Results First Received: November 23, 2009
Last Updated: June 6, 2014
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency